公开(公告)号：WO0119373A3

公开(公告)日：2001-10-04

申请号：PCT/US0024725

申请日：2000-09-08

Applicant: BASF AG ,  SEKUT LES ,  CARTER ADAM ,  GHAYUR TARIQ ,  BANERJEE SUBHASHIS ,  TRACEY DANIEL E

Inventor： SEKUT LES ,  CARTER ADAM ,  GHAYUR TARIQ ,  BANERJEE SUBHASHIS ,  TRACEY DANIEL E

IPC: A61K31/57 ,  A61K39/395 ,  A61K45/06 ,  C07K16/28

CPC classification number: C07K16/28 ,  A61K31/57 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2300/00

Abstract: Method for modulating responsiveness to corticosteroids in a subject are provided. In the method of the invention, an agent which antagonizes a target that regulates production of IFN- gamma in the subject is administered to the subject in combination with a corticosteroid such that responsiveness of the subject to the corticosteroid is modulated as compared to when a corticosteroid alone is administered to the subject. In one embodiment, the agent is an IL-18 antagonist. In another embodiment, the agent is an interleukin-12 (IL-12) antagonist. In yet another embodiment, the agent is an NK cell antagonist. In a preferred embodiment, the agent is an inhibitor of a caspase family protease, preferably an ICE inhibitor. In another preferred embodiment, the agent is an anti-IL-12 monoclonal antibody. In yet another preferred embodiment, the agent is an anti-asialo-GM1 antibody or an NK1.1 antibody. Other preferred agents include phosphodiesterase IV inhibitors and beta-2 agonists. The methods of the invention can be used in the treatment of a variety of inflammatory and immunological diseases and disorders. Pharmaceutical compositions comprising an agent which antagonizes a target that regulates production of IFN- gamma in a subject, a corticosteroid and a pharmaceutically acceptable carrier are also provided. A preferred composition comprises an ICE inhibitor, a corticosteroid and a pharmaceuticaly acceptable carrier.

Abstract translation: 提供了调节受试者对皮质类固醇的反应性的方法。 在本发明的方法中，将拮抗受试者中IFN-γ产生的靶标拮抗剂的试剂与皮质类固醇组合给予受试者，使得受试者对皮质类固醇的反应性与皮质类固醇相比被调节 单独对受试者施用。 在一个实施方案中，该药剂是IL-18拮抗剂。 在另一个实施方案中，该药剂是白细胞介素-12（IL-12）拮抗剂。 在另一个实施方案中，该药剂是NK细胞拮抗剂。 在优选的实施方案中，所述试剂是半胱天冬酶家族蛋白酶，优选ICE抑制剂的抑制剂。 在另一个优选的实施方案中，所述试剂是抗IL-12单克隆抗体。 在另一个优选的实施方案中，该试剂是抗脱唾液酸-GM1抗体或NK1.1抗体。 其它优选的试剂包括磷酸二酯酶IV抑制剂和β-2激动剂。 本发明的方法可用于治疗各种炎症和免疫疾病和病症。 还提供了包含拮抗受试者中的IFN-γ生成的靶的药剂，皮质类固醇和药学上可接受的载体的药物组合物。 优选的组合物包含ICE抑制剂，皮质类固醇和药物可接受的载体。

公开(公告)号：WO9841232A3

公开(公告)日：2000-10-05

申请号：PCT/US9804916

申请日：1998-03-12

Applicant: BASF AG ,  SEKUT LES ,  CARTER ADAM ,  GHAYUR TARIQ ,  BANERJEE SUBHASHIS ,  TRACEY DANIEL E

Inventor： SEKUT LES ,  CARTER ADAM ,  GHAYUR TARIQ ,  BANERJEE SUBHASHIS ,  TRACEY DANIEL E

IPC: A61K45/06 ,  A61K31/40 ,  A61K31/505 ,  A61K38/20 ,  A61K38/46 ,  A61K39/395 ,  A61P3/10 ,  A61P9/02 ,  A61P11/06 ,  A61P29/00 ,  A61P37/06 ,  A61P43/00 ,  C07K16/24 ,  A61K31/57

CPC classification number: C07K16/244 ,  A61K31/56 ,  A61K38/1793 ,  A61K45/06 ,  A61K2300/00

Abstract: Method for modulating responsiveness to corticosteroids in a subjet are provided. In the method of the invention, an agent which antagonizes a target that regulates production of IFN- gamma in the subject is administered to the subject in combination with a corticosteroid such that responsiveness of the subject to the corticosteroid is modulated as compared to when a corticosteroid alone is administered to the subject. In one embodiment, the agent is an IL-18 antagonist. In another embodiment, the agent is an interleukin-12 (IL-12) antagonist. In yet another embodiment, the agent is an NK cell antagonist. In a preferred embodiment, the agent is an inhibitor of a caspase family protease, preferably an ICE inhibitor. In another preferred embodiment, the agent is an anti-IL-12 monoclonal antibody. In yet another preferred embodiment, the agent is an anti-asialo-GM1 antibody or an NK1.1 antibody. Other preferred agents include phosphodiesterase IV inhibitors and beta-2 agonists. The methods of the invention can be used in the treatment of a variety of inflammatory and immunological diseases and disorders. Pharmaceutical compositions comprising an agent which antagonizes a target that regulates production of IFN- gamma in a subject, a corticosteroid and a pharmaceutically acceptable carrier are also provided. A preferred composition comprises an ICE inhibitor, a corticosteroid and a pharmaceutically acceptable carrier.

Abstract translation: 提供了一种用于调节子流体中对皮质类固醇的反应性的方法。 在本发明的方法中，将拮抗受试者中IFN-γ产生的靶标拮抗剂的试剂与皮质类固醇组合给予受试者，使得受试者对皮质类固醇的反应性与皮质类固醇相比被调节 单独对受试者施用。 在一个实施方案中，该药剂是IL-18拮抗剂。 在另一个实施方案中，该药剂是白细胞介素-12（IL-12）拮抗剂。 在另一个实施方案中，该药剂是NK细胞拮抗剂。 在优选的实施方案中，所述试剂是半胱天冬酶家族蛋白酶，优选ICE抑制剂的抑制剂。 在另一个优选的实施方案中，所述试剂是抗IL-12单克隆抗体。 在另一个优选的实施方案中，该试剂是抗脱唾液酸-GM1抗体或NK1.1抗体。 其它优选的试剂包括磷酸二酯酶IV抑制剂和β-2激动剂。 本发明的方法可用于治疗各种炎症和免疫疾病和病症。 还提供了包含拮抗受试者中的IFN-γ生成的靶的药剂，皮质类固醇和药学上可接受的载体的药物组合物。 优选的组合物包含ICE抑制剂，皮质类固醇和药学上可接受的载体。

公开(公告)号：AU7127600A

公开(公告)日：2001-04-17

申请号：AU7127600

申请日：2000-09-08

Applicant: BASF AG

Inventor： SEKUT LES ,  CARTER ADAM ,  GHAYUR TARIQ ,  BANERJEE SUBHASHIS ,  TRACEY DANIEL E

IPC: A61K31/57 ,  A61K39/395 ,  A61K45/06 ,  C07K16/28

公开(公告)号：SK122199A3

公开(公告)日：2000-12-11

申请号：SK122199

申请日：1998-03-12

Applicant: BASF AG

Inventor： SEKUT LES ,  CARTER ADAM ,  GHAYUR TARIQ ,  BANERJEE SUBHASHIS ,  TRACEY DANIEL E

IPC: A61K31/40 ,  A61K45/06 ,  A61K31/505 ,  A61K38/20 ,  A61K38/46 ,  A61K39/395 ,  A61P3/10 ,  A61P9/02 ,  A61P11/06 ,  A61P29/00 ,  A61P37/06 ,  A61P43/00 ,  C07K16/24 ,  A61K39/00

Abstract: Method for modulating responsiveness to corticosteroids in a subjet are provided. In the method of the invention, an agent which antagonizes a target that regulates production of IFN- gamma in the subject is administered to the subject in combination with a corticosteroid such that responsiveness of the subject to the corticosteroid is modulated as compared to when a corticosteroid alone is administered to the subject. In one embodiment, the agent is an IL-18 antagonist. In another embodiment, the agent is an interleukin-12 (IL-12) antagonist. In yet another embodiment, the agent is an NK cell antagonist. In a preferred embodiment, the agent is an inhibitor of a caspase family protease, preferably an ICE inhibitor. In another preferred embodiment, the agent is an anti-IL-12 monoclonal antibody. In yet another preferred embodiment, the agent is an anti-asialo-GM1 antibody or an NK1.1 antibody. Other preferred agents include phosphodiesterase IV inhibitors and beta-2 agonists. The methods of the invention can be used in the treatment of a variety of inflammatory and immunological diseases and disorders. Pharmaceutical compositions comprising an agent which antagonizes a target that regulates production of IFN- gamma in a subject, a corticosteroid and a pharmaceutically acceptable carrier are also provided. A preferred composition comprises an ICE inhibitor, a corticosteroid and a pharmaceutically acceptable carrier.

公开(公告)号：ES2146192T1

公开(公告)日：2000-08-01

申请号：ES98912929

申请日：1998-03-12

Applicant: BASF AG

Inventor： SEKUT LES ,  CARTER ADAM ,  GHAYUR TARIQ ,  BANERJEE SUBHASHIS ,  TRACEY DANIEL E

IPC: A61K31/40 ,  A61K45/06 ,  A61K31/505 ,  A61K38/20 ,  A61K38/46 ,  A61K39/395 ,  A61P3/10 ,  A61P9/02 ,  A61P11/06 ,  A61P29/00 ,  A61P37/06 ,  A61P43/00 ,  C07K16/24 ,  A61K39/00

Abstract: Method for modulating responsiveness to corticosteroids in a subjet are provided. In the method of the invention, an agent which antagonizes a target that regulates production of IFN- gamma in the subject is administered to the subject in combination with a corticosteroid such that responsiveness of the subject to the corticosteroid is modulated as compared to when a corticosteroid alone is administered to the subject. In one embodiment, the agent is an IL-18 antagonist. In another embodiment, the agent is an interleukin-12 (IL-12) antagonist. In yet another embodiment, the agent is an NK cell antagonist. In a preferred embodiment, the agent is an inhibitor of a caspase family protease, preferably an ICE inhibitor. In another preferred embodiment, the agent is an anti-IL-12 monoclonal antibody. In yet another preferred embodiment, the agent is an anti-asialo-GM1 antibody or an NK1.1 antibody. Other preferred agents include phosphodiesterase IV inhibitors and beta-2 agonists. The methods of the invention can be used in the treatment of a variety of inflammatory and immunological diseases and disorders. Pharmaceutical compositions comprising an agent which antagonizes a target that regulates production of IFN- gamma in a subject, a corticosteroid and a pharmaceutically acceptable carrier are also provided. A preferred composition comprises an ICE inhibitor, a corticosteroid and a pharmaceutically acceptable carrier.

公开(公告)号：TR9902615T2

公开(公告)日：2000-03-21

申请号：TR9902615

申请日：1998-03-12

Applicant: BASF AG

Inventor： SEKUT LES ,  CARTER ADAM ,  GHAYUR TARIQ ,  BANERJEE SUBHASHIS ,  TRACEY DANIEL E

IPC: A61K45/06 ,  A61K31/40 ,  A61K31/505 ,  A61K38/20 ,  A61K38/46 ,  A61K39/395 ,  A61P3/10 ,  A61P9/02 ,  A61P11/06 ,  A61P29/00 ,  A61P37/06 ,  A61P43/00 ,  C07K16/24 ,  A61K39/00

CPC classification number: C07K16/244 ,  A61K31/56 ,  A61K38/1793 ,  A61K45/06 ,  A61K2300/00

公开(公告)号：NZ337769A

公开(公告)日：2002-09-27

申请号：NZ33776998

申请日：1998-03-12

Applicant: BASF AG

Inventor： SEKUT LES ,  CARTER ADAM ,  GHAYUR TARIQ ,  BANERJEE SUBHASHIS ,  TRACEY DANIEL E

IPC: A61K31/40 ,  A61K31/505 ,  A61K45/06 ,  A61K38/20 ,  A61K38/46 ,  A61K39/395 ,  A61P3/10 ,  A61P9/02 ,  A61P11/06 ,  A61P29/00 ,  A61P37/06 ,  A61P43/00 ,  C07K16/24

Abstract: An agent which antagonises a target that regulates production of interferon-g (IFN-g) for the use in the manufacture of a medicament comprising a corticosteroid for modulating responsiveness to the corticosteroid in a subject suffering from an auto inflammatory or auto immune disease or disorder.

公开(公告)号：SI20110A

公开(公告)日：2000-06-30

申请号：SI9820032

申请日：1998-03-12

Applicant: BASF AG

Inventor： SEKUT LES ,  CARTER ADAM ,  GHAYUR TARIQ ,  BANERJEE SUBHASHIS ,  TRACEY DANIEL E

IPC: A61K31/40 ,  A61K31/505 ,  A61K38/20 ,  A61K38/46 ,  A61K45/06 ,  A61K39/395 ,  A61P3/10 ,  A61P9/02 ,  A61P11/06 ,  A61P29/00 ,  A61P37/06 ,  A61P43/00 ,  C07K16/24 ,  A61K31/573

Abstract: Method for modulating responsiveness to corticosteroids in a subjet are provided. In the method of the invention, an agent which antagonizes a target that regulates production of IFN-'gamma' in the subject is administered to the subject in combination with a corticosteroid such that responsiveness of the subject to the corticosteroid is modulated as compared to when a corticosteroid alone is administered to the subject. In one embodiment, the agent is an IL-18 antagonist. In another embodiment, the agent is an interleukin-12 (IL-12) antagonist. In yet another embodiment, the agent is an NK cell antagonist. In a preferred embodiment, the agent is an inhibitor of a caspase family protease, preferably an ICE inhibitor. In another preferred embodiment, the agent is an anti-IL-12 monoclonal antibody. In yet another preferred embodiment, the agent is an anti-asialo-GM1 antibody or an NK1.1 antibody. Other preferred agents include phosphodiesterase IV inhibitors and beta-2 agonists. The methods of the invention can be used in the treatment of a variety of inflammatory and immunological diseases and disorders. Pharmaceutical compositions comprising an agent which antagonizes a target that regulates production of IFN-'gamma' in a subject, a corticosteroid and a pharmaceutically acceptable carrier are also provided. A preferred composition comprises an ICE inhibitor, a corticosteroid and a pharmaceutically acceptable carrier.

公开(公告)号：PL336464A1

公开(公告)日：2000-06-19

申请号：PL33646498

申请日：1998-03-12

Applicant: BASF AG

Inventor： SEKUT LES ,  CARTER ADAM ,  GHAYUR TARIQ ,  BANERJEE SUBHASHIS ,  TRACEY DANIEL E

IPC: A61K31/40 ,  A61K45/06 ,  A61K31/505 ,  A61K38/20 ,  A61K38/46 ,  A61K39/395 ,  A61P3/10 ,  A61P9/02 ,  A61P11/06 ,  A61P29/00 ,  A61P37/06 ,  A61P43/00 ,  C07K16/24 ,  A61K39/00

Abstract: Method for modulating responsiveness to corticosteroids in a subjet are provided. In the method of the invention, an agent which antagonizes a target that regulates production of IFN- gamma in the subject is administered to the subject in combination with a corticosteroid such that responsiveness of the subject to the corticosteroid is modulated as compared to when a corticosteroid alone is administered to the subject. In one embodiment, the agent is an IL-18 antagonist. In another embodiment, the agent is an interleukin-12 (IL-12) antagonist. In yet another embodiment, the agent is an NK cell antagonist. In a preferred embodiment, the agent is an inhibitor of a caspase family protease, preferably an ICE inhibitor. In another preferred embodiment, the agent is an anti-IL-12 monoclonal antibody. In yet another preferred embodiment, the agent is an anti-asialo-GM1 antibody or an NK1.1 antibody. Other preferred agents include phosphodiesterase IV inhibitors and beta-2 agonists. The methods of the invention can be used in the treatment of a variety of inflammatory and immunological diseases and disorders. Pharmaceutical compositions comprising an agent which antagonizes a target that regulates production of IFN- gamma in a subject, a corticosteroid and a pharmaceutically acceptable carrier are also provided. A preferred composition comprises an ICE inhibitor, a corticosteroid and a pharmaceutically acceptable carrier.

公开(公告)号：CA2282845A1

公开(公告)日：1998-09-24

申请号：CA2282845

申请日：1998-03-12

Applicant: BASF AG

Inventor： GHAYUR TARIQ ,  BANERJEE SUBHASHIS ,  CARTER ADAM ,  TRACEY DANIEL E ,  SEKUT LES

IPC: A61K45/06 ,  A61K31/40 ,  A61K31/505 ,  A61K38/20 ,  A61K38/46 ,  A61K39/395 ,  A61P3/10 ,  A61P9/02 ,  A61P11/06 ,  A61P29/00 ,  A61P37/06 ,  A61P43/00 ,  C07K16/24 ,  A61K39/00

Abstract: Method for modulating responsiveness to corticosteroids in a subjet are provided. In the method of the invention, an agent which antagonizes a target that regulates production of IFN-.gamma. in the subject is administered to the subject in combination with a corticosteroid such that responsiveness of the subject to the corticosteroid is modulated as compared to when a corticosteroid alone is administered to the subject. In one embodiment, the agent is an IL-18 antagonist. In another embodiment, the agent is an interleukin-12 (IL-12) antagonist. In yet another embodiment, the agent is an NK cell antagonist. In a preferred embodiment, the agent is an inhibitor of a caspase family protease, preferably an ICE inhibitor. In another preferred embodiment, the agent is an anti-IL-12 monoclonal antibody. In yet another preferred embodiment, the agent is an anti-asialo-GM1 antibody or an NK1.1 antibody. Other preferred agents include phosphodiesterase IV inhibitors and beta-2 agonists. The methods of the invention can be used in the treatment of a variety of inflammatory and immunological diseases and disorders. Pharmaceutical compositions comprising an agent which antagonizes a target that regulates production of IFN-.gamma. in a subject, a corticosteroid and a pharmaceutically acceptable carrier are also provided. A preferred composition comprises an ICE inhibitor, a corticosteroid and a pharmaceutically acceptable carrier.